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AbstrAct
Introduction As cancer survivors continue to live 
longer, the incidence of second primary cancers (SPCs) 
will also rise. Relatively little is understood about the 
diagnostic pathway for SPCs, how people appraise, 
interpret symptoms and seek help for a second different 
cancer and the experiences (including challenges) of 
healthcare providers relating to SPCs. This study aims to 
systematically appraise and synthesise the literature on 
the pathways to diagnosis of an SPC and the associated 
patient and healthcare provider experiences.
Methods The approach taken includes systematic 
searches of published and unpublished literature without 
any date or language restrictions. MEDLINE, Embase, CAB 
Abstracts, MEDLINE In-Process and non-indexed citations, 
PsycINFO, Epub Ahead of Print, In-Process and other non-
indexed citations, Ovid MEDLINE Daily, CINAHL, ASSIA, 
Sociological Abstracts, Web of Science, PROSPERO and 
grey literature will be searched to identify observational, 
systematic reviews, mixed methods and qualitative 
studies of interest. Titles, abstracts and full texts will be 
screened against the inclusion–exclusion criteria by at 
least two reviewers independently. Relevant outcomes of 
interest and study and population characteristics will be 
extracted. Synthesis will be used guided by the Pathways 
to Treatment model and the Olesen model of time intervals.
Ethics and dissemination Ethical approval is not 
required. This systematic review will provide a deeper 
understanding of the complex and heterogeneous 
diagnostic pathways of SPCs, while identifying common 
themes across the diagnostic interval, routes to diagnosis 
and patient and healthcare provider experiences. These 
findings will help provide a nuanced picture of the 
diagnostic pathway for SPCs that may inform policy and 
consistent practice. In particular, approaches to early 
diagnosis for an SPC; including the timing and reasons 
behind the decision by the patient to seek care,the 
challenges faced by healthcare providers, and in the 
development of future interventions to reduce the delay in 
patient time-to-presentation.
PrOsPErO registration number CRD42016051692.
IntrOductIOn
The number of people surviving cancer 
is steadily increasing.1 As cancer survivors 
continue to live longer, in common with the 
wider population, the incidence of second 
primary cancers (SPCs) is also expected to 
grow.2 SPC has been defined as a new primary 
cancer that occurs in a person who has had 
cancer in the past.3 Evidence suggests that the 
incidence of SPCs among cancer survivors 
ranges between 1% and 17% depending on 
the index cancer site,4–13 with SPCs estimated 
to account for as much as 16%–18% of total 
cancer incidence14–16 in western countries.
Fear of a cancer recurring and the possi-
bility of getting a new primary cancer or 
multiple primaries are often a source of worry 
and psychosocial distress among cancer survi-
vors.17–19 These cancer-related health worries 
have been linked to higher levels of mental 
illness particularly anxiety and depression 
in long-term survivors.17 Furthermore, the 
fear of and past experiences of cancer have 
been shown to affect patients’ help-seeking 
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Protocol
strengths and limitations of this study
 ► This is the first systematic review to appraise 
and synthesise the literature on the pathways to 
diagnosis of a second primary cancer (SPC) and 
the associated patient and healthcare provider 
experiences.
 ► This study may help provide a nuanced picture 
of the diagnostic pathway for SPCs that may 
inform policy and consistent practice in particular 
approaches to early diagnosis for an SPC, including 
the timing and reasons behind the decision by the 
patient to seek care and the challenges faced by 
healthcare providers, and in the development of 
future interventions.
 ► The review is not restricted to any time period or 
specific languages.
 ► We anticipate that the available data from qualitative 
studies may be limited (as informed by an initial 
scoping exercise) and as such, metaethnography 
synthesis may not be possible to do.
 ► It is unlikely that a meta-analysis will be applicable 
for the quantitative studies included because 
the scope of this review does not cover survival 
outcomes along the diagnostic pathway for SPCs.
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Figure 1 Pathways to Treatment model24. HCP, healthcare professional.
Figure 2 Model of key time points and intervals (as adapted from Weller et al).33
behaviour.20–23 Symptoms of an SPC may be missed if 
patients are not aware of their significance.20 This could 
be because of patients focusing on the symptoms of the 
original cancer only or patients’ perceptions being influ-
enced by the presence of comorbid conditions.24–26
Early detection of cancers is an important element in 
improving cancer outcomes, as the stage of disease at 
diagnosis is linked to survival for many cancers.20 25 While 
patients’ ability to recognise possible warning signs and 
taking prompt action is a critical early step, evidence 
suggests that the patient diagnostic pathway is often not 
straightforward.27–31 For example, the diagnostic interval 
may vary depending on the route to diagnosis, which 
has potential implications for the stage at diagnosis. The 
pathways to treatment model24 provides a theoretical 
framework for the wide range of factors that influence 
the pathway to diagnosis, those relating to the patient and 
those linked to the healthcare provider, the health system 
and the cancer itself (figure 1). There are also key time 
points in diagnostic journeys (Olesen et al32 and Weller et 
al33 as illustrated in figure 2). Both models emphasise the 
often complex journeys that patients go through from the 
onset of first symptoms to the start of treatment.
A greater understanding of patient pathways to diag-
nosis (including diagnostic routes) for an SPC is vital due 
to the growing incidence, yet comparatively little is known 
about these pathways. Mapping the evidence on pathways 
to diagnosis for an SPC and the associated patient and 
healthcare providers’ experiences will be an important 
starting point that will provide a nuanced picture of the 
diagnostic pathway for SPCs. These insights may help 
to inform policy and consistent practice in approaches 
to early diagnosis for an SPC, including the timing and 
the decision by the patient to seek care, and in the devel-
opment of future interventions to reduce the delay in 
patient time-to-presentation.
This review aims to systematically appraise and synthe-
sise the literature on pathways to diagnosis of an SPC and 
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Table 1 Inclusion–exclusion criteria 
Inclusion Exclusion
Pathways to 
diagnosis
 ► Any stage of the pathway to diagnosis for an SPC
 ► Appraisal, help-seeking, diagnostic and pretreatment 
intervals
 ► Routes to diagnosis
 ► Pathways to diagnosis for recurrent FPCs or 
metastatic cancers
 ► Studies focusing only on the time between 
the diagnosis of an FPC and SPC
Patients  ► SPCs in patients above 18 years of age
 ► Patients diagnosed with FPC at 18 years and above
 ► SPCs in children and adolescents
 ► SPCs in adults following a childhood or 
adolescent FPC
Healthcare 
providers
 ► Healthcare providers involved in the diagnosis and 
management of patients with SPC in the diagnostic 
pathway
Key outcomes 
of interest
 ► Pathways to diagnosis for SPCs as per the inclusion criteria 
above
 ► How patients appraise, interpret symptoms and engage 
with healthcare in the diagnosis of an SPC
 ► Healthcare provider experiences, perspectives and 
challenges faced around the pathways to diagnosis of an 
SPC
 ► Patient and healthcare provider experiences 
related to pathways to diagnosis for 
recurrent FPCs or metastatic cancers
Setting  ► Primary, secondary or tertiary care in any country
Study designs  ► Cohort, case–control and cross-sectional studies
 ► Systematic reviews and mixed methods
 ► Qualitative studies such as interviews, focus group 
discussions and ethnography on the pathways to diagnosis 
for any SPC and associated patient and healthcare provider 
experiences
 ► RCTs
 ► Studies using secondary datasets 
or conference abstracts, conference 
proceedings and book chapters that are 
not focused on the diagnostic pathways for 
an SPC or patient/provider experiences of 
SPCs
 ► Case reports
FPC, First Primart Cancer; RCT, Randomised Control Trial; SPC, Second Primary Cancer. 
associated patient and healthcare provider experiences. 
Our objectives are:
1. To summarise the literature describing pathways to 
diagnosis of an SPC, including any descriptions of pa-
tient and diagnostic intervals and routes to diagnosis;
2. To summarise the literature describing how patients 
appraise symptoms and engage with healthcare in the 
pathway to diagnosis of an SPC;
3. To explore the available evidence on healthcare pro-
viders’ perspectives around the pathways to diagnosis 
of an SPC and the challenges they face.
MEthOds
The PRISMA-P (Preferred Reporting Items for System-
atic Review and Meta-Analysis Protocols) statement34 has 
guided the development and reporting of this systematic 
review protocol.
Inclusion and exclusion criteria
Table 1 summarises the inclusion–exclusion criteria. This 
review will consider studies that report on any stage of 
the pathways to diagnosis for an SPC, including routes 
to diagnosis (eg, during routine follow-up or surveillance 
relating to the first cancer, through engagement with 
screening, symptomatic presentation in general practice 
or through emergency presentation). We will also consider 
studies that report on patient and diagnostic intervals 
such as symptom appraisal, help-seeking behaviour, diag-
nostic and pretreatment intervals.24 28 33 We will follow 
the definitions of appraisal, help-seeking, diagnostic and 
pretreatment intervals as defined in the Aarhus state-
ment.33 Although these definitions are important in this 
review, we will not exclude studies because of lack of or 
poor definitions only.
Studies that report on how patients appraise and inter-
pret symptoms, engage with healthcare in the diagnosis of 
an SPC and on routes to diagnosis, will also be included. 
Studies for inclusion will be limited to those that examine 
patients with SPCs only and where patients are 18 years 
and above at the time of first primary cancer (FPC) diag-
nosis. We recognise that SPCs in adults following a child-
hood or adolescent primary cancer is an important area, 
and there is substantial work that has been done on the 
late effects of childhood cancers that include SPCs.35 
However, this population group has unique characteris-
tics, thus such studies will not be eligible for inclusion.
We will include studies that report on healthcare 
providers' experiences including perspectives on the 
challenges they face around the pathways to diagnosis of 
an SPC. Exclusions will be made for studies that report 
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box 1 Example search strategy for MEdLInE(r)
1. exp second primary cancer/
2. second primary cancer$.ti,ab.
3. second primary malignan$.ti,ab.
4. second primary tumo$r$.ti,ab.
5. second primary neoplasm$.ti,ab.
6. or/1–5 [SPC TERMS]
7. (patient experience$ or patient know$ or patient perception$ 
or patient perspective$ or patient view$ or patient interpret$ or 
patient understand$ or patient aware$ or patient attitude).ti,ab.
8. ((health$care provider$ or health$care personnel or health$care 
professional$ or health$care practitioner$ or doctor$ or general 
practitioner$ or GP$ or consultant$) adj2 (experience$ or 
challenge$ or view$ or understanding$)).ti,ab.
9. or/7–8 [PATIENT & PROVIDER TERMS]
10. pathway$ to diagnos$.ti,ab.
11. diagnos$ journey.ti,ab.
12. diagnos$ pathway$.ti.
13. diagnos$ pathway$.ti,ab.
14. (diagnos$ adj2 pathway$).ti,ab.
15. route$ to diagnos$.ti,ab.
16. diagnos$ route$.ti,ab.
17. pathway$ to treatment$.ti,ab.
18. (patient appraisal or help$seeking behavio$r$ or diagnos$ 
interval$ or pre$treatment interval$).ti,ab.
19. (first symptom or first presentation or clinical appearance or first 
investigation or first referral or first specialist visit or diagnosis or 
treatment start).ti,ab.
20. ((patient appraisal and self$ management) or decision to 
consult health$care provider or health$care provider appraisal, 
investigations, referrals, appointment$ or planning or scheduling 
treatment).ti,ab.
21. or/10–20 [PATHWAYS TO DIAGNOSIS TERMS]
22. 9 or 21 [PATIENTS & PROVIDER TERMS AND PATHWAYS TO 
DIAGNOSIS TERMS)
23. 6 and 22 [CANCER TERMS AND PATIENTS & PROVIDER TERMS 
AND PATHWAYS TO DIAGNOSIS TERMS COMBINED]
24. limit 23 to humans [LIMITED TO HUMAN ONLY STUDIES]
on pathways to diagnosis for recurrent FPCs or meta-
static cancers and their associated patient and provider 
experiences.
We will consider studies from any country conducted 
in primary, secondary or tertiary setting that are focused 
on the pathways to diagnosis for an SPC. Furthermore, 
experiences of healthcare providers around the pathways 
to diagnosis for an SPC in any setting will be eligible for 
inclusion.
Eligible study designs include observational studies 
such as cohort, case–control and cross-sectional studies 
that report on the pathways to diagnosis for any type of 
SPC. Systematic reviews, mixed methods and qualitative 
studies such as interviews, focus group discussions and 
ethnography reporting on the pathways to diagnosis for 
any SPC and associated patient and healthcare provider 
experiences will also be eligible for inclusion. It is 
unlikely that study designs such as randomised controlled 
trials (RCTs) will describe the pathways to diagnosis for an 
SPC and/or patient and provider experiences along that 
pathway as they are often focused on interventions, thus, 
such studies will be excluded. Furthermore, conference 
abstracts, case reports, book chapters and studies that use 
secondary datasets that are not focused on the diagnostic 
pathways for an SPC or patient/provider experiences 
will be excluded. In addition, if these studies do not have 
complete study methodologies, findings and discussion 
sections, they will also be excluded from the review.
search strategy
We will search published and unpublished literature with 
no restrictions on the date or language to minimise selec-
tion bias. A search strategy of relevant Medical Subject 
Headings terms was designed, piloted and then further 
refined (box 1).
To identify relevant published studies, the search 
strategy will be run initially in MEDLINE through the 
OVID platform. It will then be adapted, and suitable 
changes will be made before re-running it again in 
Embase, CAB Abstracts, MEDLINE In-Process and non-in-
dexed citations, PsycINFO, Epub Ahead of Print, In-Pro-
cess and other non-indexed citations and Ovid MEDLINE 
Daily. Other sources such as CINAHL, ASSIA, Sociolog-
ical Abstracts, Web of Science and PROSEPRO will also 
be searched, and the search strategy adapted accordingly. 
References lists of relevant studies identified will also be 
scrutinised for any potential additional studies.
To identify relevant studies from unpublished liter-
atures, we will search grey literature in Open Grey, 
ProQuest Dissertations and Theses Global databases for 
reports and theses.
screening and data extraction
All the citations found from the various databases will 
be imported into EndNote X7. Independently, two 
reviewers (LK and AB) will screen the titles and abstracts 
against the inclusion and exclusion criteria. Another 
two reviewers (CC and DC) will independently screen a 
minimum of 10% of these titles and abstracts to check 
for consistency. Full texts of all potentially relevant arti-
cles will be retrieved and again screened by at least two 
reviewers independently to ascertain whether they have 
met the inclusion–exclusion criteria. Any disagreements 
will be resolved through team discussions.
A data extraction form will be designed and piloted 
to ensure that it captures all the relevant data. The 
included studies will be divided between reviewers, where 
one reviewer will carry out the data extraction of the 
first half and the second reviewer will carry out the data 
extraction of the second half. Both reviewers will do this 
independently and then countercheck each other’s data 
extraction.
The data extraction form will include key charac-
teristics of the studies such as author, publication year, 
period of the study (by year(s)), data source, country of 
study, study design and setting (ie, primary, secondary 
or tertiary care) and type of healthcare system including 
first point of contact with the healthcare provider. In 
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Table 2 Quality assessment tools 
Tools Study designs
CASP checklist Systematic review
Case–control
Cohorts
Qualitative (eg, interviews, 
focus group discussions and 
ethnography)
McMaster Critical Review 
Tool and STROBE
Cross-sectional
Before and after
MMAT Mixed methods
Aarhus checklist All included studies that report 
and measure intervals of patient 
cancer journey
CASP, Critical Appraisal Skills Programme; MMAT, Mixed 
Methods Appraisal Tool; STROBE, STrengthening the Reporting of 
Observational Studies in Epidemiology.
addition, characteristics of the study population such age, 
gender, ethnicity and cancer types will be included which 
will provide the context for explanations and interpreta-
tions. Any information on the pathways to diagnosis for 
an SPC will be extracted. This includes routes to diag-
nosis, the onset of first symptoms, first presentation or 
first contact with the healthcare provider, first investiga-
tion of cancer-related symptoms, referral to hospital, first 
specialist visit, diagnosis and start of treatment. Further-
more, information on appraisal, help-seeking, diag-
nostic and pretreatment intervals will also be extracted. 
Any other relevant patient and provider experiences 
(including challenges) for SPCs along the diagnostic 
pathway will also be extracted.
Quality assessment
Quality assessment will be carried out in parallel to 
data extraction. The quality assessment tool will vary 
depending on the study design of the included article. 
There is currently no consensus as to which instrument 
is ‘best’ for assessing observational studies, especially of 
non-intervention studies. Therefore, we plan to adapt 
several published tools as shown in table 2. We will use 
the Critical Appraisal Skills Programme (CASP) tool for 
systematic reviews, case–control and cohort studies. The 
CASP tool for qualitative studies will also be used. Within 
the literature on the synthesis of qualitative studies, it 
has been argued that appraisal tools focus more on the 
methodological rather than the conceptual strengths.36 37 
Therefore, in order to ensure that the authors’ theoret-
ical insights are captured, qualitative studies will not be 
excluded because of the quality of the methods alone.
The McMaster Critical Review tool will be adapted for 
cross-sectional and before after studies guided by the 
STROBE statement.38–40 The Mixed Methods Appraisal 
Tool developed by the National Collaborating Centre for 
Methods and Tools at McMaster University will be used 
for mixed methods studies.41
We will also apply the Aarhus checklist as a frame-
work for describing the rigour of papers to studies that 
describe and measure intervals on the pathways to cancer 
diagnosis for an SPC. The Aarhus checklist was developed 
as a resource for early diagnosis research that describes 
and measures intervals in patient cancer journeys.33
data synthesis
We are uncertain of the profile of study types that we will 
uncover, although we anticipate most will be descriptive 
studies. As such, data synthesis will depend on the type of 
papers identified. Tables and diagrams or charts will be 
used to summarise the findings as appropriate. Depending 
on the included papers, synthesis will consider different 
categorisations of findings to explore. For example, 
varying combinations of FPC and SPCs, patterns over 
time and different healthcare delivery systems.
For the qualitative studies, we anticipate that the avail-
able data will be limited (as informed by an initial scoping 
exercise) and as such, metaethnography analysis will not 
be appropriate. Therefore, a narrative framework will be 
used to summarise and describe the available evidence 
of pathways to diagnosis of an SPC.42 Similarly, narrative 
synthesis will be used to summarise findings from quan-
titative studies. It is unlikely that a meta-analysis will be 
applicable because the scope of this review is not intended 
to cover survival outcomes along the diagnostic pathway 
for SPCs. Where information on routes to detection is 
available, these will be analysed separately.
Increasingly, narrative synthesis in systematic reviews 
has been used as a way of collating evidence from research 
that has been conducted by a range of methods.43 
Although it has been criticised for its lack of transparency, 
we plan to be explicit in how we identify key concepts 
and themes across individual studies. The two models 
of pathways to cancer diagnosis mentioned earlier, the 
Pathways to Treatment model24 and the Olesen model of 
time intervals32 as adapted by Weller et al33 will guide the 
synthesis.
We will first start by developing a preliminary synthesis 
and exploring the relationships within and across studies. 
NVIVO 10 will facilitate the process of comparing and 
contrasting information across the included studies 
where possible, which will allow for indexing and coding 
of themes to be done systematically. The focus of the 
synthesis will be to map out a comparison of the included 
studies against the model of Pathways to Treatment and 
the model of time intervals. It is anticipated that this 
comparison will lead to the identification of key find-
ings of similarities and differences within and across the 
included studies.
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